Johnson & Johnson has bought Auris Health, Inc. for about $3.4 billion in cash, with additional payments of up to $2.35 billion, in the aggregate, which may be payable upon reaching certain predetermined milestones, JJ said in a statement Monday.
With Auris Health’s robotic platform technology, currently used in diagnostic and therapeutic procedures in the lung, Johnson & Johnson will advance its commitment to combatting lung cancer and expand its digital surgery portfolio across multiple surgical specialties, the JJ said in the press release.
Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices, Johnson & Johnson said that the passionate team and differentiated innovation from Auris will help the company amplify the power of digital surgery to address unmet clinical needs and lead a transformation in surgical care and lung cancer intervention.
The Auris technology complements robotic platform technologies currently in development in general surgery with Verb Surgical, through the Johnson & Johnsoncollaboration with Verily, and in orthopaedics with the acquisition of Orthotaxy, Johnson & Johnson said.